HFA
INO icon

Hoover Financial Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Hoover Financial Advisors’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$0 Hold
1
– – ﹤0.01% 668
2021
Q1 		$0 Buy
+1
New +$132 ﹤0.01% 620

Other funds holding INO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Hoover Financial Advisors's INO Position: Q2 2021 in Review

Hoover Financial Advisors held its Inovio Pharmaceuticals (INO) position steady in Q2 2021 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #668.

Hoover Financial Advisors first reported a position in INO in Q1 2021 and has held it in 2 quarters since. 211 funds tracked by Wall St. Rank hold INO as of Q2 2021.

  • Hoover Financial Advisors held 1 share of Inovio Pharmaceuticals worth $0 as of Q2 2021.
  • Hoover Financial Advisors left its Inovio Pharmaceuticals share count unchanged in Q2 2021.
  • Inovio Pharmaceuticals made up ﹤0.01% of Hoover Financial Advisors's portfolio in Q2 2021, its #668 holding.
  • Hoover Financial Advisors first reported a position in Inovio Pharmaceuticals in Q1 2021 and has held it in 2 quarters since.
  • 211 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2021.

Based on Hoover Financial Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.